Abstract
Hypertension is a leading cardiovascular risk for cardiovascular morbidity and mortality. Age is the strongest risk factor for dementia and with the increasing life expectancy the number of patients living with dementia worldwide is estimated to progressively rise. A number of studies support an association between hypertension, particularly in midlife, and the development of cognitive disorders and dementia, including Alzheimer's disease. According to this, considering hypertension as a possible modifiable risk factor for the cognitive decline is of great clinical interest.
Treatment of hypertension in midlife seems to promote considerable benefits with regard to cardiovascular outcomes. Longitudinal studies examining the possible benefit of anti-hypertensive treatments on cognitive decline have produced promising results. Nevertheless, the results from randomised controlled clinical trials on treatment of hypertension are not conclusive for the effect on cognitive decline and dementia. New randomized controlled trials are needed to definitively clarify clinical advantages and specifically elucidate the relationship between anti-hypertensive treatments and cognitive function or dementia.
Keywords: Cognitive function, hypertension, blood pressure, cognitive decline, dementia, Alzheimer's disease, vascular dementia, beta-amyloid, hypoxia, atherosclerosis
Current Pharmaceutical Design
Title: Cognitive Decline as a Consequence of Essential Hypertension
Volume: 17 Issue: 28
Author(s): Davide Grassi, Livia Ferri, Paola Cheli, Paolo Di Giosia and Claudio Ferri
Affiliation:
Keywords: Cognitive function, hypertension, blood pressure, cognitive decline, dementia, Alzheimer's disease, vascular dementia, beta-amyloid, hypoxia, atherosclerosis
Abstract: Hypertension is a leading cardiovascular risk for cardiovascular morbidity and mortality. Age is the strongest risk factor for dementia and with the increasing life expectancy the number of patients living with dementia worldwide is estimated to progressively rise. A number of studies support an association between hypertension, particularly in midlife, and the development of cognitive disorders and dementia, including Alzheimer's disease. According to this, considering hypertension as a possible modifiable risk factor for the cognitive decline is of great clinical interest.
Treatment of hypertension in midlife seems to promote considerable benefits with regard to cardiovascular outcomes. Longitudinal studies examining the possible benefit of anti-hypertensive treatments on cognitive decline have produced promising results. Nevertheless, the results from randomised controlled clinical trials on treatment of hypertension are not conclusive for the effect on cognitive decline and dementia. New randomized controlled trials are needed to definitively clarify clinical advantages and specifically elucidate the relationship between anti-hypertensive treatments and cognitive function or dementia.
Export Options
About this article
Cite this article as:
Grassi Davide, Ferri Livia, Cheli Paola, Di Giosia Paolo and Ferri Claudio, Cognitive Decline as a Consequence of Essential Hypertension, Current Pharmaceutical Design 2011; 17 (28) . https://dx.doi.org/10.2174/138161211798157685
DOI https://dx.doi.org/10.2174/138161211798157685 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Ginkgo biloba as an Alternative Medicine in the Treatment of Anxiety in Dementia and other Psychiatric Disorders
Current Drug Metabolism Cognitive Dysfunction in Major Depressive Disorder: A State-of-the-Art Clinical Review
CNS & Neurological Disorders - Drug Targets Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Ion Channels and Epilepsy
Current Pharmaceutical Design Leptin Reduces Infarct Size in Association with Enhanced Expression of CB2, TRPV1, SIRT-1 and Leptin Receptor
Current Neurovascular Research Strategies to Diminish the Ab Load in Alzheimers Disease
Current Medicinal Chemistry - Central Nervous System Agents Targeting Epigenetics in Nervous System Disease
CNS & Neurological Disorders - Drug Targets Why and How We Should Treat Elderly Patients with Hypertension?
Current Vascular Pharmacology Neurotrophic and Neuroprotective Effects of Muscle Contraction
Current Pharmaceutical Design Ramelteon in the Treatment of Delirium: New Perspectives from Reported Findings and a Case Observation
Current Drug Therapy Baseline MRI Predictors of Conversion from MCI to Probable AD in the ADNI Cohort
Current Alzheimer Research Introduction: Advancing Drug Discovery for Alzheimers Disease [ ISOA Fifth Annual Investigators Meeting “Recent Advances in Drug Discovery and Development for Alzheimers Disease” Sponsored by Elan Pharmaceuticals Inc, The Graphic Expression, Glaxo Smith Kline Pharmaceuticals, Neurochem Inc, Pfizer Inc. (Guest Editors: Howard M. Fillit and Lorenzo M. Refolo)]
Current Alzheimer Research Cannabinoids and Schizophrenia: Therapeutic Prospects
Current Pharmaceutical Design Novel Circular, Cyclic and Acyclic ψ(CH2O) Containing Peptide Inhibitors of SKI- 1/S1P: Synthesis, Kinetic and Biochemical Evaluations
Current Medicinal Chemistry The Role of Therapeutic Drugs on Acquired Mitochondrial Toxicity
Current Drug Metabolism Medicinal Chemistry of Antimigraine Drugs
Current Medicinal Chemistry Integration of <sup>18</sup>FDG-PET Metabolic and Functional Connectomes in the Early Diagnosis and Prognosis of the Alzheimer's Disease
Current Alzheimer Research A Comprehensive Investigation of Molecular Signatures and Pathways Linking Alzheimer’s Disease and Epilepsy <i>via</i> Bioinformatic Approaches
Current Alzheimer Research Nonconvulsive (Dialeptic) Status Epilepticus in Children
Current Pediatric Reviews Editorial Review 2015
Current Radiopharmaceuticals